Xspray Pharma AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XSPRAY.ST research report →
Companywww.xspraypharma.com
Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017.
- CEO
- Per Andersson
- IPO
- 2017
- Employees
- 27
- HQ
- Solna, SE
Price Chart
Valuation
- Market Cap
- $1.20B
- P/E
- -6.43
- P/S
- 0.00
- P/B
- 1.86
- EV/EBITDA
- -8.60
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -27.99%
- ROIC
- -21.14%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-171,443,000 · 39.95%
- EPS
- $-4.46 · 48.26%
- Op Income
- $-161,853,000
- FCF YoY
- 26.97%
Performance & Tape
- 52W High
- $64.10
- 52W Low
- $22.46
- 50D MA
- $26.32
- 200D MA
- $31.70
- Beta
- -0.06
- Avg Volume
- 77.41K
Get TickerSpark's AI analysis on XSPRAY.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our XSPRAY.ST Coverage
We haven't published any research on XSPRAY.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate XSPRAY.ST Report →